AR054595A1 - Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis - Google Patents
Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosisInfo
- Publication number
- AR054595A1 AR054595A1 ARP060103292A ARP060103292A AR054595A1 AR 054595 A1 AR054595 A1 AR 054595A1 AR P060103292 A ARP060103292 A AR P060103292A AR P060103292 A ARP060103292 A AR P060103292A AR 054595 A1 AR054595 A1 AR 054595A1
- Authority
- AR
- Argentina
- Prior art keywords
- guanfacine
- single dose
- pharmaceutical formulations
- daily administration
- administration form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Formulaciones terapéuticas de guanfacina en forma de una unica dosis una vez al día que tienen tamano total de tableta util.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70298205P | 2005-07-28 | 2005-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054595A1 true AR054595A1 (es) | 2007-06-27 |
Family
ID=37668083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060103292A AR054595A1 (es) | 2005-07-28 | 2006-07-28 | Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis |
Country Status (18)
Country | Link |
---|---|
US (1) | US20070048371A1 (es) |
EP (1) | EP1909766B1 (es) |
JP (2) | JP5726401B2 (es) |
KR (1) | KR20080041669A (es) |
CN (1) | CN101252917A (es) |
AR (1) | AR054595A1 (es) |
AU (1) | AU2006275718B8 (es) |
BR (1) | BRPI0615989B8 (es) |
CA (1) | CA2616181C (es) |
DK (1) | DK1909766T3 (es) |
ES (1) | ES2566395T3 (es) |
IL (1) | IL188980A0 (es) |
NO (1) | NO20081038L (es) |
NZ (1) | NZ565649A (es) |
RU (1) | RU2435573C2 (es) |
TW (1) | TW200744672A (es) |
WO (1) | WO2007016284A2 (es) |
ZA (1) | ZA200801575B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0916163D0 (en) * | 2009-09-15 | 2009-10-28 | Shire Llc | Prodrugs of guanfacine |
ES2733133T3 (es) * | 2010-02-03 | 2019-11-27 | Pharma Two B Ltd | Formulaciones de liberación prolongada de rasagilina y sus usos |
AU2011265293A1 (en) * | 2010-06-11 | 2013-01-24 | Shire Llc | Combination therapy with lisdexamphetamine and extended release guanfacine |
US20120041068A1 (en) * | 2010-08-11 | 2012-02-16 | Aptapharma, Inc. | Extended Release Pharmaceutical Preparations for Active Pharmaceutical Ingredients with pH Dependent Solubility |
CN102525983A (zh) * | 2010-12-31 | 2012-07-04 | 北京万全阳光医药科技有限公司 | 胍法新缓释片及其制备方法 |
CN102579381B (zh) * | 2012-03-30 | 2013-07-10 | 河南中帅医药科技发展有限公司 | 盐酸胍法辛缓释制剂及其制备方法 |
CN105188677A (zh) | 2013-03-13 | 2015-12-23 | 特瑞斯制药股份有限公司 | 苯佐那酯调释固体片剂和胶囊剂 |
US9180104B2 (en) * | 2013-03-13 | 2015-11-10 | Tris Pharma, Inc. | Benzonatate modified release solid tablets and capsules |
WO2016089997A1 (en) | 2014-12-02 | 2016-06-09 | Yale University | Methods of preventing neurodegeneration of association cortex in a mammal |
SG11201804100UA (en) * | 2015-12-08 | 2018-06-28 | Ardea Biosciences Inc | Pharmaceutical composition comprising a potent inhibitor of urat1 |
JP6656670B2 (ja) * | 2016-03-11 | 2020-03-04 | 国立大学法人 鹿児島大学 | 抗hcv活性を有する薬剤 |
HUE059844T2 (hu) * | 2016-04-20 | 2023-01-28 | New Frontier Labs Llc | Azelainsav-észterek az inzulin-rezisztencia kezelésében |
WO2019136224A1 (en) * | 2018-01-05 | 2019-07-11 | Shire Human Genetic Therapies, Inc. | Amphetamine-guanfacine combinations for treatment of neuropsychiatric disorders |
EP4292587A1 (en) | 2022-06-15 | 2023-12-20 | Sawai Pharmaceutical Co., Ltd. | Guanfacine hydrochloride containing pharmaceutical preparation |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH649918A5 (de) * | 1981-07-09 | 1985-06-28 | Sandoz Ag | Verwendung von n-amidino-2-phenylacetamiden als wirkstoff zur herstellung von pharmazeutischen zubereitungen gegen schizophrenie. |
IE56999B1 (en) * | 1983-12-22 | 1992-03-11 | Elan Corp Plc | Pharmaceutical formulation |
US5102668A (en) * | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
US5854290A (en) * | 1995-09-21 | 1998-12-29 | Amy F. T. Arnsten | Use of guanfacine in the treatment of behavioral disorders |
DE19834573A1 (de) * | 1998-07-31 | 2000-02-03 | Bayer Ag | Doppelmetallcyanid-Katalysatoren für die Herstellung von Polyetherpolyolen |
FR2781152B1 (fr) * | 1998-07-20 | 2001-07-06 | Permatec Tech Ag | Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation |
PE20001396A1 (es) * | 1999-01-18 | 2000-12-23 | Gruenenthal Chemie | Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista |
US6635277B2 (en) * | 2000-04-12 | 2003-10-21 | Wockhardt Limited | Composition for pulsatile delivery of diltiazem and process of manufacture |
US6287599B1 (en) * | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
DK1355633T3 (da) * | 2001-12-19 | 2005-04-04 | Astrazeneca Ab | Ny filmcoating, der indeholder en ethylacrylat/methylmethacrylat-copolymer og polyvinylacetat |
US6811794B2 (en) * | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
ATE401860T1 (de) * | 2002-03-29 | 2008-08-15 | Alza Corp | Volumensparende arzneiform zur kontrollierten freisetzung |
US6763509B2 (en) * | 2002-09-26 | 2004-07-13 | Sun Microsystems, Inc. | Method and apparatus for allocating decoupling capacitor cells |
US20070104782A1 (en) * | 2005-07-28 | 2007-05-10 | Ibrahim Melissa E | Modified release tablet formulations with enhanced mechanical properties |
-
2006
- 2006-07-27 NZ NZ565649A patent/NZ565649A/en unknown
- 2006-07-27 RU RU2008102911/15A patent/RU2435573C2/ru active
- 2006-07-27 DK DK06788707.5T patent/DK1909766T3/en active
- 2006-07-27 EP EP06788707.5A patent/EP1909766B1/en active Active
- 2006-07-27 CA CA2616181A patent/CA2616181C/en not_active Expired - Fee Related
- 2006-07-27 KR KR1020087004755A patent/KR20080041669A/ko not_active Application Discontinuation
- 2006-07-27 BR BRPI0615989A patent/BRPI0615989B8/pt active IP Right Grant
- 2006-07-27 ES ES06788707.5T patent/ES2566395T3/es active Active
- 2006-07-27 AU AU2006275718A patent/AU2006275718B8/en active Active
- 2006-07-27 JP JP2008524162A patent/JP5726401B2/ja active Active
- 2006-07-27 CN CNA2006800313902A patent/CN101252917A/zh active Pending
- 2006-07-27 WO PCT/US2006/029277 patent/WO2007016284A2/en active Application Filing
- 2006-07-27 US US11/493,914 patent/US20070048371A1/en not_active Abandoned
- 2006-07-28 AR ARP060103292A patent/AR054595A1/es unknown
- 2006-07-28 TW TW095127856A patent/TW200744672A/zh unknown
-
2008
- 2008-01-23 IL IL188980A patent/IL188980A0/en unknown
- 2008-02-18 ZA ZA200801575A patent/ZA200801575B/xx unknown
- 2008-02-27 NO NO20081038A patent/NO20081038L/no not_active Application Discontinuation
-
2012
- 2012-07-17 JP JP2012158337A patent/JP2012229253A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DK1909766T3 (en) | 2016-04-04 |
EP1909766B1 (en) | 2016-03-16 |
TW200744672A (en) | 2007-12-16 |
JP2009502951A (ja) | 2009-01-29 |
RU2435573C2 (ru) | 2011-12-10 |
ES2566395T3 (es) | 2016-04-12 |
AU2006275718B2 (en) | 2012-10-04 |
BRPI0615989A2 (pt) | 2011-05-31 |
BRPI0615989B1 (pt) | 2020-05-26 |
WO2007016284A3 (en) | 2007-03-29 |
ZA200801575B (en) | 2008-12-31 |
WO2007016284A2 (en) | 2007-02-08 |
CN101252917A (zh) | 2008-08-27 |
NZ565649A (en) | 2011-03-31 |
JP2012229253A (ja) | 2012-11-22 |
AU2006275718B8 (en) | 2012-11-01 |
US20070048371A1 (en) | 2007-03-01 |
IL188980A0 (en) | 2008-08-07 |
CA2616181C (en) | 2015-02-17 |
CA2616181A1 (en) | 2007-02-08 |
NO20081038L (no) | 2008-04-23 |
EP1909766A2 (en) | 2008-04-16 |
AU2006275718A8 (en) | 2012-11-01 |
BRPI0615989B8 (pt) | 2021-05-25 |
AU2006275718A1 (en) | 2007-02-08 |
KR20080041669A (ko) | 2008-05-13 |
RU2008102911A (ru) | 2009-09-10 |
JP5726401B2 (ja) | 2015-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054595A1 (es) | Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis | |
ECSP10010224A (es) | Formulaciones líquidas de hormona luteinizante (lh). | |
BR112012008317A2 (pt) | produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal | |
ECSP066534A (es) | Formas de dosificacion de oxicodona de liberacion controlada, orales, una vez al dia | |
AR045972A1 (es) | Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas | |
GT200600260A (es) | Derivados de benzamida y usos relacionados con los mismos | |
CO6400186A2 (es) | Tabletas de acetato de ulipristal | |
SG194756A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
EA201170512A1 (ru) | Композиция для перорального введения | |
NO20082097L (no) | Farmasoytiske sammensetninger | |
CY1114933T1 (el) | Στερεες φαρμακευτικες συνθεσεις σταθερης δοσης περιεχουσες ιρβεσαρτανη και αμλοδιπινη, η παρασκευη τους και η θεραπευτικη εφαρμογη τους | |
BRPI0508596A (pt) | combinação compreendendo ligante alfa-2-delta | |
ECSP10010052A (es) | Formulaciones galenicas de alisquireno y valsartan | |
CL2008000610A1 (es) | Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor. | |
TR200903036A2 (tr) | Tiyokolşikozit ve non-steroidal anti-enflamatuar ilaç kombinasyonları | |
TR200806300A2 (tr) | Çözünürlük artırıcı farmasötlk formulasyon | |
ATE460934T1 (de) | Pharmazeutische zubereitungen von ciprofloxacin | |
CO6351711A2 (es) | Combinacion de dosis fija en la forma de una tableta de dos copas o de una sola capa de alisquireno y amlodipina | |
MA31227B1 (fr) | Composition pharmaceutique renfermant du phloroglucinol et du paracetamol. | |
PA8802001A1 (es) | Combinación antiretroviral novedosa | |
EA201290378A1 (ru) | Композиции, содержащие нестероидные противовоспалительные лекарственные средства | |
AR067351A1 (es) | Combinacion de picotamida con nafronil | |
CL2007002762A1 (es) | Composicion farmaceutica que comprende orlistat 60mg y rosuvastatina calcica equivalente a 5mg de rosuvastatina en una sola unidad de dosis, util para el tratamiento de la obesidad y la dislipidemia. | |
ATE357220T1 (de) | Pharmazeutische zusammensetzung mit modifizierter freisetzung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |